TickerFacts.

Estrella Immunopharma, Inc. (ESLA): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$1.79M
Year ended 2025-12-31
-$9.38M
Trailing 12 months to 2026-06-30
2021-12-31: -$316.2K2023-06-30: -$1.34M2024-06-30: -$16.07M2025-12-31: -$1.79M-$1.79M
2021-12-31 Operating Cash Flow (USD) 2025-12-31
Period endedOperating Cash FlowChange YoYSource filing
2025-12-31-$1.79Mn/a2026-03-18, From 2025-01-01
No annual figure between 2024-06-30 and 2025-12-31.
2024-06-30-$16.07Mn/m2024-09-27, From 2023-07-01
2023-06-30-$1.34Mn/a2024-09-27, From 2022-07-01
No annual figure between 2021-12-31 and 2023-06-30.
2021-12-31-$316.2Kn/a2023-03-14, From 2021-01-06

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating Cash FlowChange YoY
Estrella Immunopharma, Inc. (ESLA)2025-12-31-$1.79Mn/a
BioCardia, Inc. (BCDA)2025-12-31-$7.44Mn/m
Cero Therapeutics Holdings, Inc. (CERO)2025-12-31-$16.10Mn/a
Tevogen Inc. (TVGN)2025-12-31-$12.33Mn/m
Eloxx Pharmaceuticals, Inc. (ELOX)2025-12-31-$6.33Mn/m
AIM ImmunoTech Inc. (AIM)2025-12-31-$10.96Mn/m
Exozymes Inc. (EXOZ)2025-12-31-$6.50Mn/m
Zivo Bioscience, Inc. (ZIVO)2024-12-31-$4.31Mn/m
Zeo ScientifiX, Inc. (ZEOX)2025-10-31-$718.0Kn/m

Compare ESLA, BCDA, CERO, TVGN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗